Alaska Permanent Fund Corp Grows Stake in Exelixis, Inc. (NASDAQ:EXEL)

Alaska Permanent Fund Corp grew its holdings in Exelixis, Inc. (NASDAQ:EXEL) by 28.8% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 52,622 shares of the biotechnology company’s stock after acquiring an additional 11,767 shares during the quarter. Alaska Permanent Fund Corp’s holdings in Exelixis were worth $1,262,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in the business. CWM LLC grew its stake in Exelixis by 17.3% during the 3rd quarter. CWM LLC now owns 7,698 shares of the biotechnology company’s stock worth $168,000 after buying an additional 1,136 shares during the last quarter. SG Americas Securities LLC purchased a new position in Exelixis during the 3rd quarter worth approximately $1,742,000. Ballentine Partners LLC purchased a new position in Exelixis during the 3rd quarter worth approximately $301,000. Denali Advisors LLC grew its stake in Exelixis by 7,995.2% during the 3rd quarter. Denali Advisors LLC now owns 1,700 shares of the biotechnology company’s stock worth $37,000 after buying an additional 1,679 shares during the last quarter. Finally, Commonwealth Equity Services LLC lifted its position in Exelixis by 4.0% during the 3rd quarter. Commonwealth Equity Services LLC now owns 120,479 shares of the biotechnology company’s stock worth $2,632,000 after acquiring an additional 4,639 shares during the period. Hedge funds and other institutional investors own 85.27% of the company’s stock.

Exelixis Price Performance

NASDAQ EXEL opened at $23.53 on Friday. Exelixis, Inc. has a 1-year low of $18.08 and a 1-year high of $24.34. The company has a market capitalization of $6.94 billion, a P/E ratio of 36.77, a PEG ratio of 0.63 and a beta of 0.54. The business has a 50 day moving average price of $22.73 and a 200 day moving average price of $22.17.

Exelixis (NASDAQ:EXEL) last announced its quarterly earnings data on Tuesday, February 6th. The biotechnology company reported $0.27 EPS for the quarter, beating analysts’ consensus estimates of $0.25 by $0.02. The business had revenue of $479.65 million during the quarter, compared to the consensus estimate of $481.23 million. Exelixis had a return on equity of 8.57% and a net margin of 11.35%. On average, research analysts expect that Exelixis, Inc. will post 1.21 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on EXEL. JMP Securities reaffirmed a “market outperform” rating and set a $27.00 price objective on shares of Exelixis in a research report on Wednesday, April 10th. Stifel Nicolaus increased their price objective on Exelixis from $23.00 to $25.00 and gave the stock a “hold” rating in a research report on Friday, February 2nd. TheStreet raised Exelixis from a “c+” rating to a “b-” rating in a research report on Monday, March 18th. William Blair reaffirmed an “outperform” rating on shares of Exelixis in a research report on Friday, January 26th. Finally, Barclays cut Exelixis from an “overweight” rating to an “equal weight” rating and set a $25.00 price objective for the company. in a research report on Thursday, April 11th. Six investment analysts have rated the stock with a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $26.29.

Insider Activity at Exelixis

In other news, Director David Edward Johnson bought 190,000 shares of the business’s stock in a transaction on Wednesday, February 21st. The stock was purchased at an average cost of $20.70 per share, for a total transaction of $3,933,000.00. Following the completion of the transaction, the director now directly owns 1,100,730 shares of the company’s stock, valued at approximately $22,785,111. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Exelixis news, EVP Patrick J. Haley sold 47,020 shares of Exelixis stock in a transaction on Friday, February 23rd. The shares were sold at an average price of $21.45, for a total value of $1,008,579.00. Following the sale, the executive vice president now directly owns 384,866 shares in the company, valued at approximately $8,255,375.70. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director David Edward Johnson purchased 190,000 shares of the stock in a transaction on Wednesday, February 21st. The stock was acquired at an average price of $20.70 per share, for a total transaction of $3,933,000.00. Following the completion of the purchase, the director now directly owns 1,100,730 shares in the company, valued at approximately $22,785,111. The disclosure for this purchase can be found here. 2.90% of the stock is owned by insiders.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.